Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank54
5Y CAGR-3.4%
Year-over-Year Change
Year-over-year revenue growth rate
5Y CAGR
-3.4%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.90% |
| Q3 2025 | 3.77% |
| Q2 2025 | 7.02% |
| Q1 2025 | -4.87% |
| Q4 2024 | 5.05% |
| Q3 2024 | 4.77% |
| Q2 2024 | -1.55% |
| Q1 2024 | 6.73% |
| Q4 2023 | 1.38% |
| Q3 2023 | -0.39% |
| Q2 2023 | 4.99% |
| Q1 2023 | 3.13% |
| Q4 2022 | -1.35% |
| Q3 2022 | 6.29% |
| Q2 2022 | 4.71% |
| Q1 2022 | 1.20% |
| Q4 2021 | 4.46% |
| Q3 2021 | 10.64% |
| Q2 2021 | 4.01% |
| Q1 2021 | 5.93% |
| Q4 2020 | 5.82% |
| Q3 2020 | 0.90% |
| Q2 2020 | 0.62% |
| Q1 2020 | 7.21% |
| Q4 2019 | 48.79% |
| Q3 2019 | 0.91% |
| Q2 2019 | 9.65% |
| Q1 2019 | -1.34% |
| Q4 2018 | 10.91% |
| Q3 2018 | 4.30% |
| Q2 2018 | 17.38% |
| Q1 2018 | -1.66% |
| Q4 2017 | 12.71% |
| Q3 2017 | 6.25% |
| Q2 2017 | -23.87% |
| Q1 2017 | 55.81% |
| Q4 2016 | 10.86% |
| Q3 2016 | -4.13% |
| Q2 2016 | 8.42% |
| Q1 2016 | -4.75% |